Key result
NSAIDs (both coxibs and traditional NSAIDs) are associated with a 35% increased risk of myocardial infarction, highlighting the need for personalized risk management using biochemical markers.
The cardiovascular toxicity of NSAIDs, including etoricoxib, is driven by COX-2 inhibition and prostacyclin suppression, suggesting a role for biochemical markers in personalizing therapy to minimize thrombotic risk.
No takes yet. Share an insight, caveat, or question.
May support cautious NSAID use in high-risk patients; leaves open validation of biochemical markers for personalization.
Paola Patrignani (2008) conducted a review in Cardiovascular and gastrointestinal toxicity of NSAIDs. NSAIDs (coxibs and traditional NSAIDs) was evaluated. NSAIDs (both coxibs and traditional NSAIDs) are associated with a 35% increased risk of myocardial infarction, highlighting the need for personalized risk management using biochemical markers.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: